Routes of
administration Oral, IV Formula C21H23F2N3O4 Molar mass 419.42 g/mol | ChemSpider 9721013 3D model (Jmol) Interactive image | |
 | ||
JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.
References
JNJ-Q2 Wikipedia(Text) CC BY-SA